1. A method of making glass, the method comprising
adding iron to a glass batch at least partially in the form of melite, and melting the glass batch to form a glass having a visible transmission (Lta) no greater than 28% and an IR transmission no greater than 7%; and
wherein the glass includes a colorant portion comprising:
total iron:
0.7 to 1.8%
cobalt oxide:
0.001 to 1.0%
titanium oxide:
0.25 to 3.0%
chromium oxide:
0 to 0.010%.
2. A method of making glass, the method comprising
adding iron to a glass batch at least partially in the form of melite, and melting the glass batch to form a glass having a visible transmission (Lta) no greater than 28%; and
wherein the glass includes a colorant portion comprising:
total iron:
\u20030.7 to 1.8%
cobalt oxide:
0.001 to 1.0%
titanium oxide:
\u20020.25 to 3.0%
chromium oxide:
\u2009\u2003\u20020 to 0.010%.
3. The method of claim 2, wherein the glass has a dominant wavelength of from 450 to 530 nm, and an excitation purity (Pe) of from 10 to 25%.
4. The method of claim 3, wherein said dominant wavelength and excitation purity are measured at a nominal thickness of the glass of anywhere from 3 mm to 4 mm.
5. The method of claim 2, wherein the glass is substantially free of cerium.
6. The method of claim 2, wherein the glass is substantially free of nickel.
7. The method of claim 2, wherein the glass has a visible transmission (Lta) no greater than 25% and an JR transmission no greater than 5%.
8. The method of claim 2, wherein the glass has a visible transmission (Lta) no greater than 20% and an JR transmission no greater than 7%.
9. A method of making glass, the method comprising
adding iron to a glass batch at least partially in the form of melite, and melting the glass batch to form a glass having a visible transmission (Lta) no greater than 28%; and
wherein the glass includes a colorant portion comprising from 0 to 0.010% chromium oxide.
10. The method of claim 9, wherein the colorant portion comprises at least two of the following three elements:
total iron:
\u20030.7 to 1.8%
cobalt oxide:
0.001 to 1.0%
titanium oxide:
\u20020.25 to 3.0%.
11. The method of claim 9, wherein the glass has a dominant wavelength of from 450 to 530 nm, and an excitation purity (Pe) of from 10 to 25%.
12. The method of claim 11, wherein said dominant wavelength and excitation purity are measured at a nominal thickness of the glass of anywhere from 3 mm to 4 mm.
13. The method of claim 9, wherein the glass is substantially free of cerium.
14. The method of claim 9, wherein the glass is substantially free of nickel.
15. The method of claim 9, wherein the glass has a visible transmission (Lta) no greater than 25% and an IR transmission no greater than 5%.
16. The method of claim 9, wherein the glass has a visible transmission (Lta) no greater than 20% and an IR transmission no greater than 7%.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. A method of treating ocular hypertension which comprises administering to a mammal having ocular hypertension a therapeutically effective amount of a compound represented by formula I:
24
wherein the hatched segment represents an bond, the solid triangle represents a bond, the wavy segment represents or bond, dashed lines represent a double bond or a single bond, X is selected from the group consisting of hydrogen and halogen radicals, R3 is heteroaryl or a substituted heteroaryl radical, R1 and R2 are independently selected from the group consisting of hydrogen or a lower alkyl radical having up to six carbon atoms, or a lower acyl radical having up to six carbon atoms, R is selected from the group consisting of CO2R4, CONR42, CH2OR4, CONR4SO2R4, P(O)(OR4) and
25
wherein R4 is selected from the group consisting of H, phenyl and lower alkyl having from one to six carbon atoms and n is 0 or an integer of from 1 to 4.
2. The method of claim 1 wherein the substituent on the heteroaryl radical is selected from the group consisting of C1 to C6 alkyl; OR4; CO2R4; halogen, trifluoromethyl; COR4; COCF3; SO2NR4, NO2; and CN.
3. The method of claim 2 wherein said compound is represented by formula II:
26
wherein Z is selected from the group consisting of O and S, A is selected from the group consisting of N, CH, and C, R5 is selected from the group consisting of hydrogen, halogen, lower alkyl having from 1 to 6 carbon atoms, and lower alkoxy having from 1 to 6 carbon atoms, R6 and R7 are selected from the group consisting of hydrogen, halogen, lower alkyl having from 1 to 6 carbon atoms, lower alkoxy having from 1 to 6 carbon atoms or, together with
27
, R6 and R7 forms a condensed aryl ring.
4. The method of claim 3 wherein said compound is represented by formula III:
28
5. The method of claim 4 wherein the dashed line represents a double bond.
6. The method of claim 4 wherein the dashed line represents a single bond.
7. The method of claim 5 wherein R is CO2R4 and R4 is H.
8. The method of claim 6 wherein R is CO2R4 and R4 is H.
9. The method of claim 5 wherein R is CO2R4 and R4 is methyl.
10. The method of claim 6 wherein R is CO2R4 and R4 is methyl.
11. The method of claim 4 wherein R is CO2R4.
12. The method of claim 11 wherein R4 is selected from the group consisting of H and lower alkyl.
13. The method of claim 4 wherein A is C and R5, R6 and R7 are H.
14. The method of claim 1 wherein X is selected from the group consisting of hydrogen, fluoro and chloro radicals.
15. The method of claim 14 wherein X is hydrogen.
16. The method of claim 14 wherein X is fluoro.
17. The method of claim 14 wherein X is chloro.
18. The method of claim 1 wherein said compound is 7-(1R,2R,3R)-3-Hydroxy-2-(E)-4-hydroxy-4-(1-(5-chloro-thiophen-2-yl)methyl-cyclobutyl)but-1-enyl-5-chloro-cyclopentylhept-5-enoic acid methyl ester.
19. The method of claim 1 wherein said compound is 7-(1R,2R,3R)-3-Hydroxy-2-(E)-4-hydroxy-4-(1-(5-chloro-thiophen-2-yl)methylcyclobutyl)but-1-enyl-5-chlorocyclopentylhept-5-enoic acid.
20. The method of claim 1 wherein said compound is
(Z)-7-(1R,2R,3R)-3-Hydroxy-2-(E)-4-hydroxy-4-(1-(5-chloro-thiophen-2-yl)-methylcyclobutyl)but-1-enyl-5-fluoro-cyclopentylhept-5-enoic acid methyl ester
21. The method of claim 1 wherein said compound is
(Z)-7-(1R,2R,3R)-3-Hydroxy-2-(E)-4-hydroxy-4-(1-(5-chloro-thiophen-2-methylcyclobutyl)but-1-enyl-5-fluoro-cyclopentylhept-5-enoic acid.
22. An ophthalmic solution comprising a therapeutically effective amount of a compound of formula I, as defined in claim 1, or a pharmaceutically acceptable salt thereof, in admixture with a non-toxic, ophthalmically acceptable liquid vehicle, packaged in a container suitable for metered application.
23. The ophthalmic solution of claim 22 wherein said compound is a compound of Formula III.
24. A pharmaceutical product, comprising a container adapted to dispense the contents of said container in metered form; and an ophthalmic solution in said container comprising a compound of formula I as defined in claim 1, or a pharmaceutically acceptable salt thereof, in admixture with a non-toxic, ophthalmically acceptable liquid vehicle.
25. The product of claim 24 wherein said compound is a compound of Formula III.
26. The compound represented by formula I:
29
wherein the hatched segment represents an bond, the solid triangle represents a bond, the wavy segment represents an or bond, dashed lines represent a double bond or a single bond, X is selected from the group consisting of hydrogen and halogen radicals, R3 is heteroaryl or a substituted heteroaryl radical, R1 and R2 are independently selected from the group consisting of hydrogen or a lower alkyl radical having up to six carbon atoms, or a lower acyl radical having up to six carbon atoms, R is selected from the group consisting of CO2R4, CONR42, CH2OR4, CONR4SO2R4, P(O)(OR4) and
30
wherein R4 is selected from the group consisting of H, phenyl and lower alkyl having from one to six carbon atoms and n is 0 or an integer of from 1 to 4.
27. The compound of claim 26 wherein R is CO2R4.
28. The compound of claim 27 wherein R4 is selected from the group consisting of H and lower alkyl.
29. The compound of claim 28 wherein said compound is represented by the formula
31
30. The compound of claim 29 wherein A is C and R5, R6 and R7 are H.
31. The compound of claim 30 wherein said compound is selected from the group consisting of:
7-(1R,2R,3R)-3-Hydroxy-2-(E)-4-hydroxy-4-(1-(5-chloro-thiophen-2-yl)-methyl-cyclobutyl)but-1-enyl-5-chloro-cyclopentylhept-5-enoic acid methyl ester,
7-(1R,2R,3R)-3-Hydroxy-2-(E)-4-hydroxy-4-(1-(5-chloro-thiophen-2-yl)methylcyclobutyl)but-1-enyl-5-chlorocyclopentylhept-5-enoic acid,
(Z)-7-(1R,2R,3R)-3-Hydroxy-2-(E)-4-hydroxy-4-(1-(5-chloro-thiophen-2-yl)-methylcyclobutyl)but-1-enyl-5-fluoro-cyclopentylhept-5-enoic acid methyl ester,
(Z)-7-(1R,2R,3R)-3-Hydroxy-2-(E)-4-hydroxy-4-(1-(5-chloro-thiophen-2-yl)-methylcyclobutyl)but-1-enyl-5-fluoro-cyclopentylhept-5-enoic acid,
(Z)-7-(1R,2R,3R)-3-Hydroxy-2-(E)-4-hydroxy-4-(1-(5-chloro-thiophen-2-yl-methylcyclobutyl)but-1-enylcyclopentenylhept-5-enoic acid methyl ester and
(Z)-7-(1R,2R,3R)-3-Hydroxy-2-(E)-4-hydroxy-4-(1-(5-chloro-thiophen-2-yl-methylcyclobutyl)but-1-enylcyclopentenylhept-5-enoic acid.